Kairos Pharma Enters Material Definitive Agreement
Ticker: KAPA · Form: 8-K · Filed: Sep 24, 2024 · CIK: 1962011
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
Kairos Pharma just signed a big deal, filing an 8-K today.
AI Summary
On September 20, 2024, Kairos Pharma, LTD. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Los Angeles, CA, filed this 8-K report under the 1934 Securities Exchange Act.
Why It Matters
This filing indicates a significant new contract or partnership for Kairos Pharma, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new opportunities but also potential risks and obligations for the company.
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- September 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Los Angeles, CA (location) — Address of principal executive offices
- 001-42275 (identifier) — SEC File Number
FAQ
What type of material definitive agreement did Kairos Pharma, LTD. enter into?
The filing states that Kairos Pharma, LTD. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 20, 2024.
Where are Kairos Pharma, LTD.'s principal executive offices located?
Kairos Pharma, LTD.'s principal executive offices are located at 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
What is the SEC File Number for Kairos Pharma, LTD.?
The SEC File Number for Kairos Pharma, LTD. is 001-42275.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 728 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-09-24 16:22:18
Key Financial Figures
- $0 — ch registered Common Stock, par value $0.001, per share KAPA The Nasdaq Stoc
- $900,000 — ervices Agreement, the Company will pay $900,000 to PreCheck for the laboratory services
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 94KB
- ex10-1_001.jpg (GRAPHIC) — 11KB
- ex99-1.htm (EX-99.1) — 22KB
- 0001493152-24-037958.txt ( ) — 364KB
- kapa-20240920.xsd (EX-101.SCH) — 3KB
- kapa-20240920_lab.xml (EX-101.LAB) — 33KB
- kapa-20240920_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 Kairos Pharma, Ltd. (Exact name of registrant as specified in its charter) Delaware 001-42275 46-2993314 (State or other jurisdiction of incorporation) (Commission File No.) (I.R.S. Employer Identification No.) 2355 Westwood Blvd . , #139 Los Angeles CA 90064 (Address of principal executive offices) (Zip Code) (310) 948-2356 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed from last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name of each exchange on which registered Common Stock, par value $0.001, per share KAPA The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01 Entry into a Material Definitive Agreement. On September 20, 2024, Kairos Pharma, Ltd., a Delaware corporation (the "Company"), entered into a bioassay services agreement (the "Bioassay Services Agreement") with PreCheck Health Services, Inc., a Florida-based corporation ("PreCheck"). Pursuant to the Bioassay Services Agreement, PreCheck will provide certain biomarker screening services for the Company's ongoing carotuximab (ENV105) clinical trials in order to assist the Company in identifying lung and prostate cancer patients suitable to the Company's ongoing Phase 1 clinical trials for lung cancer patients and Phase 2 trials for patients with castrate resistant prostate cancer. In order to identify biomarkers for patient screening and therapy monitoring using carotuximab (ENV105), PreCheck will utilize its SolidTumorCheck+ platform for the somatic gene expression analysis of biopsy tissue samples derived from patients with lung and prostate cancer, as part of the Company's ongoing clinical trials NCT05401110 and NCT05534646. In furtherance of these efforts, PreCheck will develop a companion diagnostic to support its identification of such patients with a three gene PCR analysis or other genetic analysis, which diagnostic test will then be developed and submitted to the FDA for castrate-resistant prostate cancer patients and for lung cancer patients on Tagrisso. In exchange for PreCheck's services, and according to the terms of the Bioassay Services Agreement, the Company will pay $900,000 to PreCheck for the laboratory services. The Bioassay Services Agreement contains other customary clauses, including representations and warranties and governing law clauses. The foregoing summary of the terms and conditions of the Bioassay Services Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Bioassay Services Agreement, which is attached hereto as Exhibits 10.1 and is incorporated herein by reference. Item 8.01 Other Events. On September 24, 2024, the Company issued a press release announcing the Company's entry into the Bioassay Services Agreement with PreCheck. A copy of the press release is furnished herewith and incorporated by reference herein. Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 10.1 Bioassay Services Agreement between the Company and PreCheck, dated September 20, 2024 99.1 Press Release dated September 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 24, 2024 KAIROS PHARMA, LTD. By: /s/ John S. Yu John S. Yu Chief Executive Officer